# Pinealon

Source: https://aminodesk.com/library/pinealon
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

Pinealon is a synthetic three-amino-acid peptide (glutamate, aspartate, arginine, often written EDR) from Vladimir Khavinson's institute in St. Petersburg. It is sold for brain health and memory. There are no controlled human trials of it.

- **Legal lane:** research chemical. No approval and no US compounding route.
- **Evidence grade:** D
- **Human trials:** no randomized controlled trials
- **Related to:** [Epitalon](https://aminodesk.com/library/epitalon), from the same research group

## What it is

Pinealon belongs to the "peptide bioregulators" developed by Khavinson's group, who propose that very short peptides enter cells and adjust which genes are switched on. That idea comes almost entirely from their own laboratory and has not been taken up by mainstream pharmacology.

## What the evidence shows

The published work is in cell cultures and rodents, where the group reports less oxidative stress and better survival in nerve cells. Reviews by the same group describe Russian studies in elderly people and in people recovering from brain injury, but those were small, uncontrolled and not independently replicated.

## Dosing

**No dose established.** There is no controlled human study to take a dose from, and the injectable regimens sold online did not come from one.

## Safety

Unknown. No safety study in people has been published, and research-grade vials carry the usual risks of unverified content and sterility.

## Common questions

### Has Pinealon been tested in humans?

There are no randomized controlled trials. The Russian studies described by its developers were small, uncontrolled and not independently replicated.

### Is Pinealon related to Epitalon?

Yes. Both come from the same research group, Vladimir Khavinson's institute in St. Petersburg.

### What is the usual Pinealon dose?

No dose has been established. There is no controlled human study to take one from.

Added in the latest update. These answers summarize the sections above; sources are listed below.

## Sources

- [Khavinson et al. 2020: EDR peptide and gene expression, review in Molecules (PubMed)](https://pubmed.ncbi.nlm.nih.gov/33396470/)
- [Ilina et al. 2022: proposed mechanisms of ultrashort peptides (PubMed)](https://pubmed.ncbi.nlm.nih.gov/35457077/)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
